APR Applied Pharma Research S.A. and Labtec GmbH Announce the European Approval of Zolmitriptan Oral Dispersible Film (ODF)
3/1/2012 8:11:27 AM
More...
|
APR Applied Pharma Research S.A., Labtec GmbH and Norgine Announce the Signature of an Exclusive Licensing Agreement Under Which Norgine will Market and Distribute Setofilm™
1/18/2012 6:18:01 AM
More...
|
APR Applied Pharma Research S.A. and Labtec GmbH Announce Ondansetron Oral Dispersible Film (“ODF”) is Now Available for Licensing in Europe and Selected Non European ountries, after Having Received Marketing Authorization in Most Countries of Europe
6/13/2011 9:09:48 AM
More...
|
BioAlliance Pharma Strengthens its Proprietary Technologies with the Grant of Its Lauriad(TM) Patents in Asia and With the Transfer of Setofilm(R) Back to APR Applied Pharma Research S.A., the Owner of the Technology
6/10/2011 10:45:11 AM
More...
|
APR Applied Pharma Research S.A. Announces Participation to the Biotech Showcase 2011 Annual Conference in San Francisco Scheduled for January 10-12, 2011
12/15/2010 9:36:36 AM
More...
|
APR Applied Pharma Research S.A. and Labtec GmbH Announce Filing for Approval in Europe of Zolmitriptan Oral Dispersible Film (ODF)
12/2/2010 9:33:04 AM
More...
|
APR Applied Pharma Research S.A. and Labtec GmbH Enter Into Exclusive Licensing Agreement With Ferrer Internacional for the Registration and Marketing of Donepezil Oral Dispersible Film in Spain, Portugal and Germany
10/1/2010 8:57:20 AM
More...
|
LABORATORIOS CINFA Launches Respirub in Spain, an Innovative Formulation of a Balsamic Rub Cream, Also Available in Pediatric Formulation, Developed by APR Applied Pharma Research S.A.
9/24/2010 10:53:50 AM
More...
|
APR Applied Pharma Research S.A. and Labtec GmbH Announce the Successful Completion of the Pivotal Clinical Study on Zolmitriptan RapidFilm(R), and Its Upcoming Submission for Registration in Europe
9/15/2010 7:52:52 AM
More...
|
Nautilus Neurosciences, Inc. and APR Applied Pharma Research S.A. Announce Extension of Patent Protection for CAMBIA(TM) (Diclofenac Potassium for Oral Solution) Through 2026
9/8/2010 12:07:15 PM
More...
|
|